Tesamorelin Peptide research-grade
Tesamorelin Peptide
$47.00 $146.00Price range: $47.00 through $146.00 Select options

Tesamorelin Peptide

Price range: $47.00 through $146.00

Laboratory-grade Tesamorelin Peptide is a stabilized GHRH analog used in growth hormone–axis and metabolic peptide research. Research buyers select this listing for pre-clinical work on GHRH pathway characterization and controlled endocrine models—not for clinical, veterinary, or consumer use.

For Research Use Only. Not for human use.

For Research Use Only — Not for Human Consumption
Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Checkout

Accepted Payment Methods

For Research Use Only. Not for human use.

Tesamorelin Peptide research-grade

Overview

Laboratory-grade Tesamorelin Peptide presents as a stabilized GHRH analog used in growth hormone–axis and metabolic peptide research. Nationwide lists this SKU for controlled research programs focused on GHRH pathway characterization and controlled endocrine models—not for clinical, veterinary, or consumer use.

Research buyers specify Tesamorelin Peptide when protocols require a characterized input for GHRH pathway characterization and controlled endocrine models. Typical deployments include cell-based or cell-free assays, method development plates, and pathway-mapping models executed under institutional laboratory SOPs.

Use this entry when laboratory purchasing needs a stable research SKU for assay construction and notebook traceability. All handling of Tesamorelin Peptide must remain inside institutional research-use boundaries.

Research Context for Tesamorelin Peptide

Work involving Tesamorelin Peptide typically focuses on in vitro systems, assay development, and mechanistic model studies.

Teams confirm lot details before setup so conditions stay traceable across repeats and collaborative sites.

Published literature can inform starting ranges for related experimental designs. Each laboratory should still validate performance with its own instruments, plates, and detection chemistry.

Pilot runs are useful before committing larger plate sets, especially when detection chemistry or incubation windows are being optimized.

Documented Attributes

Key catalog attributes for this material include:

  • Research-grade material intended for laboratory investigation only
  • Catalog labeling aligned with research procurement channels
  • Suitable for method development and comparative assay workflows
  • Documentation packages available where provided for the listed lot

Laboratory Handling Notes

Receiving and Identity Checks

Before opening a vial of Tesamorelin Peptide, confirm the physical label against the purchase order and packing list.

Retain outer packaging until identity checks are complete, and report damaged seals to purchasing before experimental work continues.

Reconstitution and Aliquoting

Handle this material according to institutional SOPs for weighing, reconstitution, aliquoting, and storage.

Record lot identifiers in laboratory notebooks before reconstitution. Verify solvent compatibility and storage temperature against your validated process.

Prepare assay buffers and consumables before opening the vial to reduce hold time. Keep unused aliquots labeled with date, solvent, and concentration for later repeats.

Chain of Custody

Keep chain-of-custody notes with inventory checks when material moves between freezers or benches.

Use dedicated spatulas and clean balances to avoid cross-contamination between catalog items. Schedule thaw cycles intentionally rather than repeated freeze-thaw of the same aliquot.

Secondary containment trays reduce spill risk during multi-step reconstitution. Cold-chain interruptions should be noted even when the vial remains sealed.

Why Laboratories Source Tesamorelin Peptide

Procurement and research teams often select this catalog item because it supports:

  • Clear research-use labeling for compliance-aligned purchasing
  • Consistent product identification across multi-lot studies
  • Fit for reference, screening, and mechanistic laboratory models
  • Straightforward catalog support for planning and documentation

Study Planning and Quality Documentation

Before starting experimental work with Tesamorelin Peptide, review any COA or quality files provided with the shipment.

Align your protocol with institutional research requirements and keep use within the labeled research context.

File catalog documentation with the study records at receipt. These steps help keep experiments comparable over time when using Tesamorelin Peptide in sequential study phases.

Method Development Tips

Method development often begins with small pilot plates before larger screening panels.

Document buffer lots, incubation times, and detection settings alongside the material lot number.

If results diverge from historical baselines, re-check reconstitution volume and storage history first. Shared equipment logs help explain variance when multiple operators run the same protocol.

Inventory and Training

Update digital inventory immediately after opening a new lot of Tesamorelin Peptide.

Training new staff on labeling conventions reduces mix-ups across similar catalog SKUs. When transferring methods between sites, share both the written SOP and the lot metadata package.

Dispose of residual solutions according to institutional chemical hygiene rules. Do not repurpose research materials for any non-laboratory application.

Periodic inventory reconciliation keeps expired or depleted lots from entering active workflows. For related catalog options, browse adjacent research categories on this site after confirming your assay needs.

For Research Use Only. Not for human or animal use. Not intended to diagnose, treat, cure, or prevent any disease.

Peptide Research

For Research Use Only. Not for human use.

PubMed (NIH/NLM) records related to this compound for laboratory literature review. Inclusion does not imply suitability for any use beyond controlled research. Each note below is a research-framed summary using compliance-safe wording.

Showing 44 PubMed records. Displaying 10 per page.

  1. Author et al. (2012). Laboratory research record on Tesamorelin [PMID: 31644039]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  2. Grunfeld C et al. (2011). Laboratory research record on Tesamorelin [PMID: 21283099]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  3. Russo SC et al. (2024). Observed endpoints and laboratory profile of tesamorelin in people with HIV on… [PMID: 38905488]

    Laboratory literature summary: observed endpoints and laboratory profile of tesamorelin in people with HIV on integrase inhibitors. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  4. O'Neal R (2010). Tesamorelin update [PMID: 21591600]

    Laboratory literature summary: Tesamorelin update. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  5. Dhillon S (2011). Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy [PMID: 21668043]

    Laboratory literature summary: Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  6. Ellis RJ et al. (2025). Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal… [PMID: 39813152]

    Laboratory literature summary: Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal metabolic research models. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  7. Spooner LM et al. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy [PMID: 22298602]

    Laboratory literature summary: Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  8. Fourman LT et al. (2020). Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD [PMID: 32701508]

    Laboratory literature summary: Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  9. Lake JE et al. (2021). Tesamorelin improves fat quality independent of changes in fat quantity [PMID: 33756511]

    Laboratory literature summary: Tesamorelin improves fat quality independent of changes in fat quantity. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  10. Dhillon S (2011). Spotlight on tesamorelin in HIV-associated lipodystrophy [PMID: 22050344]

    Laboratory literature summary: Spotlight on tesamorelin in HIV-associated lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  11. Fourman LT et al. (2021). Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted… [PMID: 34006921]

    Laboratory literature summary: Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  12. González-Sales M et al. (2015). Population pharmacokinetic analysis of tesamorelin in HIV-infected research subjects… [PMID: 25358450]

    Laboratory literature summary: Population pharmacokinetic analysis of tesamorelin in HIV-infected research subjects and healthy subjects. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  13. Rahman F et al. (2023). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc… [PMID: 36845310]

    Laboratory literature summary: Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind control…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  14. Fourman LT et al. (2017). Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV [PMID: 28832410]

    Laboratory literature summary: Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  15. Badran AS et al. (2026). Laboratory research record on Tesamorelin [PMID: 41545261]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  16. Wang Y et al. (2009). Tesamorelin, a research subjects growth hormone releasing factor analogue [PMID: 19243281]

    Laboratory literature summary: Tesamorelin, a research subjects growth hormone releasing factor analogue. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  17. Stanley TL et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised,… [PMID: 31611038]

    Laboratory literature summary: Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  18. Stanley TL et al. (2011). Effects of tesamorelin on inflammatory markers in HIV research subjects with excess… [PMID: 21516030]

    Laboratory literature summary: Effects of tesamorelin on inflammatory markers in HIV research subjects with excess abdominal fat: relationship with visceral adipose…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  19. Makimura H et al. (2014). Laboratory research record on Tesamorelin [PMID: 24178787]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  20. Falutz J et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in research… [PMID: 20554713]

    Laboratory literature summary: Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in research subjects immunodeficiency virus-infected research…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  21. Tomlinson B (2006). Drug evaluation: tesamorelin, a synthetic research subjects growth hormone releasing… [PMID: 17086939]

    Laboratory literature summary: Drug evaluation: tesamorelin, a synthetic research subjects growth hormone releasing factor. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  22. Adrian S et al. (2019). The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and… [PMID: 31237318]

    Laboratory literature summary: The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  23. Teng S et al. (2013). Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the… [PMID: 27121785]

    Laboratory literature summary: Impact of Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, on the Pharmacokinetics of Simvastatin and Ritonavir in Healthy…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  24. Falutz J et al. (2008). Long-term laboratory profile and effects of tesamorelin, a growth hormone-releasing… [PMID: 18690162]

    Laboratory literature summary: Long-term laboratory profile and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV research subjects with…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  25. Stanley TL et al. (2014). Laboratory research record on Tesamorelin [PMID: 25038357]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  26. Stanley TL et al. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in… [PMID: 22495074]

    Laboratory literature summary: Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected research subjects receiving tesamorelin. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  27. Mangili A et al. (2015). Predictors of investigation Response to Tesamorelin, a Growth Hormone-Releasing Factor… [PMID: 26457580]

    Laboratory literature summary: Predictors of investigation Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected research subjects with…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  28. González-Sales M et al. (2015). Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected… [PMID: 25895899]

    Laboratory literature summary: Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected research subjects and healthy subjects. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  29. Falutz J et al. (2010). Laboratory research record on Tesamorelin [PMID: 20101189]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  30. McLarnon A (2012). Neuroendocrinology: Tesamorelin can improve cognitive function [PMID: 22926095]

    Laboratory literature summary: Neuroendocrinology: Tesamorelin can improve cognitive function. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  31. Clemmons DR et al. (2017). Laboratory research record on Tesamorelin [PMID: 28617838]

    PubMed laboratory record discussing Tesamorelin in a research context. Review the full methods and limitations on PubMed; research use only.

  32. Audsley J et al. (2019). Tesamorelin, liver fat, and NAFLD in the setting of HIV [PMID: 31611037]

    Laboratory literature summary: Tesamorelin, liver fat, and NAFLD in the setting of HIV. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  33. Traynor K (2010). FDA approves tesamorelin for HIV-related lipodystrophy [PMID: 21115997]

    Laboratory literature summary: FDA approves tesamorelin for HIV-related lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  34. Bedimo R (2011). Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy [PMID: 22096409]

    Laboratory literature summary: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  35. Ditta AM et al. (2026). Observed endpoints and laboratory profile of Tesamorelin in People Living With HIV… [PMID: 42538058]

    Laboratory literature summary: observed endpoints and laboratory profile of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  36. Patel A et al. (2011). Tesamorelin: A hope for ART-induced lipodystrophy [PMID: 21687371]

    Laboratory literature summary: Tesamorelin: A hope for ART-induced lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  37. Erlandson KM et al. (2026). Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV… [PMID: 42419889]

    Laboratory literature summary: Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a laboratory trial protocol. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  38. Berger D (2008). Tesamorelin for fat accumulation. 52-week effects and laboratory profile of… [PMID: 18724445]

    Laboratory literature summary: Tesamorelin for fat accumulation. 52-week effects and laboratory profile of tesamorelin (growth hormone releasing factor) in HIV…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  39. Grodeck B (2008). The next generation of research subjects growth hormone. How Serostim and tesamorelin… [PMID: 18828236]

    Laboratory literature summary: The next generation of research subjects growth hormone. How Serostim and tesamorelin measure up. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  40. Author et al. (2007). observed outcomes in study models and complications. Tesamorelin–results from Phase III [PMID: 17575575]

    Laboratory literature summary: observed outcomes in study models and complications. Tesamorelin–results from Phase III. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  41. Mateo MG et al. (2011). Tesamorelin for the investigation of excess abdominal fat in HIV-1-infected research… [PMID: 30764032]

    Laboratory literature summary: Tesamorelin for the investigation of excess abdominal fat in HIV-1-infected research subjects with lipodystrophy. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  42. Beach R et al. (2026). Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV:… [PMID: 42139091]

    Laboratory literature summary: Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two laboratory Cases Highlighting Distinct…. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  43. Author et al. (2007). observed outcomes in study models and complications. laboratory trials of tesamorelin in Canada [PMID: 17571443]

    Laboratory literature summary: observed outcomes in study models and complications. laboratory trials of tesamorelin in Canada. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

  44. Falutz J (2011). Tesamorelin: a novel investigational option for HIV/HAART-associated increased… [PMID: 21695284]

    Laboratory literature summary: Tesamorelin: a novel investigational option for HIV/HAART-associated increased visceral adipose tissue. Consult the PubMed record for methods, models, and limitations. Presented for research literature review only

Browse the full PubMed index: PubMed search.

Additional information

Weight .125 lbs
Dimensions 8 × 7 × .5 in
Size: No selection

5mg, 10mg, 20mg

Keep lyophilized peptides sealed in their original vial, protected from light and humidity, and store at -4°F or colder for optimal long-term stability in research settings; short-term refrigeration at around 39°F suffices for immediate use within weeks, though freezer storage maximizes integrity across extended research timelines.

Frequently Asked Questions

What is Tesamorelin peptide?

Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It is studied in research laboratories for its role in endocrine signaling and growth hormone pathway activity.

What is Tesamorelin used for in research?

Tesamorelin is used in research laboratories to investigate growth hormone signaling, receptor interactions, and metabolic pathway mechanisms. It is not approved for human use.

Is Tesamorelin Peptide approved or intended for human use?

No. Tesamorelin is strictly intended for research purposes only and is not approved by the FDA for human use.

Is Tesamorelin Peptide FDA-approved for medical or clinical use?

No. This Tesamorelin product is not approved by the U.S. Food and Drug Administration for any medical, therapeutic, or diagnostic use.

In what form is Tesamorelin supplied?

Tesamorelin is supplied as a lyophilized (freeze-dried) peptide powder for use in controlled research laboratories

How should Tesamorelin be stored?

Store sealed, lyophilized peptides protected from light and humidity at -4°F or colder; refrigeration (~39°F) is suitable for short-term use.

What vial sizes are available for Tesamorelin?

Tesamorelin is available in multiple vial sizes.

Is Tesamorelin Peptide sold as a prescription product?

No prescription is required; however, it is sold strictly for research use only.

How is Tesamorelin shipped?

Orders are processed and shipped using secure, protective packaging to maintain product integrity during transit. For more info, visit: https://www.nationwidepeptides.com/shipping-and-payments

Can Tesamorelin be used for hormone-related or health-related purposes?

Tesamorelin is studied in research laboratories for endocrine pathways; however, it is not approved for the diagnosis, experimental regimen, cure, or prevention of any disease or condition.